Portola Pharmaceuticals (NASDAQ: [[ticker:PTLA]]) has named Sheldon Koenig executive vice president and chief commercial officer. He comes to South San Francisco, CA-based Portola from Sanofi (NYSE: [[ticker:SNY]]), where he was head of the company’s cardiovascular franchise. His experience also includes leadership positions at Merck (NYSE: [[ticker:MRK]]). Portola received FDA approval last year for andexanet alfa (Andexxa), a drug that reverses the effects of blood thinners in cases of life-threatening bleeding.